Physician profile
Daniel Duc Mai
NPI 1811770134
$12,986.48
in general payments reported to CMS, 2019-2025
23 companies · $6,068 in 2025
The $6,068 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $6,919 · 2025: $6,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $27.27 · Travel and Lodging: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,949.21 |
| Education | $27.27 |
| Travel and Lodging | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,894.69 | 2024-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $1,533.51 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $1,363.01 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $1,256.55 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,030.77 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $974.58 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $870.55 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $851.25 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $639.09 | 2024-2025 | Auvelity |
| Lundbeck LLC | $538.64 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $353.43 | 2024-2025 | Trintellix |
| Noven Therapeutics, LLC | $302.57 | 2024-2025 | Xelstrym |
| Biogen, INC. | $296.70 | 2024-2025 | Zurzuvae |
| Corium, LLC | $278.27 | 2024-2025 | Azstarys |
| Alkermes, INC. | $237.04 | 2024-2025 | Aristada, Lybalvi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $172.34 | 2024 | Loreev Xr |
| Indivior INC. | $125.84 | 2024-2025 | Sublocade |
| Tris Pharma INC | $105.56 | 2024 | Quillivant, Quillichew Er, Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $48.10 | 2024 | |
| Luye Pharma (USA) LTD. | $35.61 | 2025 | Erzofri Extended-Release |
| Braeburn INC. | $28.61 | 2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $27.17 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $22.60 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.